Comphya has created CaverSTIM™, an implantable neuromodulation system that delivers sub‑sensory electrical stimulation to the cavernous nerves during the critical post‑prostatectomy healing period. By promoting nerve regeneration, the device aims to restore natural erectile function without the need for daily medication, injections, or prosthetic implants, offering urologists a restorative treatment option for nerve‑related erectile dysfunction.
Funding
$4.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Men undergoing prostatectomy often experience nerve-related erectile dysfunction, with 60–70% losing function and only about 16% regaining baseline performance. Existing treatments such as pills, injections, pumps, or prostheses address symptoms rather than promoting nerve healing, and many patients cannot tolerate these invasive or drug‑based options.
Solution
Comphya has developed CaverSTIM™, an implantable neuromodulation system designed to support the cavernous nerves responsible for erectile function. The device is implanted during prostate cancer surgery, positioning a biocompatible electrode array adjacent to the pelvic nerves and connecting it to a subcutaneous pulse generator. After a brief postoperative period, clinicians program a daily, sub‑sensory electrical stimulation protocol that runs for weeks to months, targeting the critical window of nerve regeneration. By delivering precise, low‑level stimulation, CaverSTIM™ aims to preserve nerve health, promote natural recovery, and restore erectile function without the need for daily medication or invasive prosthetic devices. Ongoing first‑in‑human and pilot studies in Australia and the United States have shown early signals of functional recovery and a favorable safety profile.
Target Audience
Primary customers are urologists and prostate cancer surgeons seeking a restorative option for patients with post‑operative erectile dysfunction, as well as hospitals and research institutions conducting clinical trials of nerve‑targeted therapies.
Features
- Implantable electrode array placed intraoperatively alongside cavernous nerves, requiring no additional surgical steps
- Subcutaneous, rechargeable pulse generator with clinician‑controlled wireless programming
- Daily neuromodulation protocol below sensory threshold to support nerve rehabilitation during the post‑operative healing phase
- Real‑time monitoring and adjustable stimulation parameters to personalize therapy
- Drug‑free approach that eliminates the need for oral PDE5 inhibitors, injections, or penile prostheses
- Designed for seamless integration into standard robotic prostatectomy workflows